Molecular therapy in urologic oncology.
During recent years, significant advances have been made in the field of molecular therapy in urologic oncology, mainly for advanced renal cell carcinoma. In this hitherto largely treatment-refractory disease, several agents have been developed targeting the von Hippel-Lindau metabolic pathway which is involved in carcinogenesis and progression of the majority of renal cell carcinomas. Although cure may not be expected, new drugs, such as the multikinase inhibitors sorafenib and sunitinib and the mammalian target of rapamycine inhibitor temsirolimus, frequently stabilize the disease course and may improve survival. Fewer data are available supporting molecular therapies in prostate, bladder, and testicular cancers. Preliminary data suggest a potential role of high-dose calcitriol and thalidomide in hormone-refractory prostate cancer, whereas targeted therapies in bladder and testicular cancers are still more or less limited to single-case experiences. The great theoretical potential and the multitude of possible targets and drug combinations, however, support further research into this exciting field of medical treatment of urologic malignancies.
Froehner
Michael
M
Department of Urology, University Hospital, Technical University of Dresden, Dresden, Germany. Michael.Froehner@uniklinikum-dresden.de
Hakenberg
Oliver W
OW
Wirth
Manfred P
MP
D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008967:Molecular Biology; D011471:Prostatic Neoplasms / Q000188:drug therapy; D014571:Urologic Neoplasms / Q000188:drug therapy*